These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21422262)

  • 1. A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog.
    Casartelli A; Lanzoni A; Comelli R; Crivellente F; Defazio R; Dorigatti R; Fasdelli N; Faustinelli I; Pagliarusco S; Tontodonati M; Cristofori P
    Toxicol Pathol; 2011 Feb; 39(2):361-71. PubMed ID: 21422262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs.
    Crivellente F; Tontodonati M; Fasdelli N; Casartelli A; Dorigatti R; Faustinelli I; Cristofori P
    Cell Biol Toxicol; 2011 Dec; 27(6):425-38. PubMed ID: 21823034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant.
    Pagliarusco S; Martinucci S; Bordini E; Miraglia L; Cufari D; Ferrari L; Pellegatti M
    Drug Metab Dispos; 2011 Feb; 39(2):283-93. PubMed ID: 20978104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
    Navari RM
    Curr Opin Investig Drugs; 2008 Jul; 9(7):774-85. PubMed ID: 18600583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
    Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
    Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
    Singla NK; Singla SK; Chung F; Kutsogiannis DJ; Blackburn L; Lane SR; Levin J; Johnson B; Pergolizzi JV
    Anesthesiology; 2010 Jul; 113(1):74-82. PubMed ID: 20526194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of drug rechallenge: the casopitant Phase III program.
    Hunt CM; Papay JI; Rich DS; Abissi CJ; Russo MW
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):539-43. PubMed ID: 20932869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret.
    Minthorn E; Mencken T; King AG; Shu A; Rominger D; Gontarek RR; Han C; Bambal R; Davis CB
    Drug Metab Dispos; 2008 Sep; 36(9):1846-52. PubMed ID: 18556439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.
    O'Brien PJ
    Toxicology; 2008 Mar; 245(3):206-18. PubMed ID: 18249481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist.
    Stokes AH; Falls JG; Yoon L; Cariello N; Faiola B; Colton HM; Jordan HL; Berridge BR
    Int J Toxicol; 2015; 34(2):151-61. PubMed ID: 25722321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.
    Germanakis I; Anagnostatou N; Kalmanti M
    Pediatr Blood Cancer; 2008 Sep; 51(3):327-33. PubMed ID: 18523992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of changes in cardiac biomarker concentrations and enzyme activities in serum after short- and long-duration transcutaneous cardiac pacing in dogs.
    Lee S; Pak SI; Hyun C
    Am J Vet Res; 2009 May; 70(5):599-603. PubMed ID: 19405898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency.
    Yamashita T; Seino Y; Ogawa A; Ogata K; Fukushima M; Tanaka K; Mizuno K
    J Cardiol; 2010 May; 55(3):377-83. PubMed ID: 20350516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.